Wearable Patches Attracting New Investment
Investors are looking beyond the wrist for health tracking, with Seveno Capital investing in PointFit for its next-gen wearable patch. The move signals a growing interest in more discreet, continuous monitoring technologies suitable for both biohacking experiments and chronic condition management.
The strategic investment in PointFit by Seveno Capital valued the Hong Kong-based startup at $10 million. This is the inaugural investment from Seveno's new Hong Kong office, a firm launched with a US$70 million commitment from entrepreneur Allen Law to back companies focused on extending human "healthspan." PointFit's technology, developed at the Hong Kong University of Science and Technology, uses an ultra-thin nanomembrane to analyze biomarkers directly from sweat, moving beyond the proxy metrics of heart rate and motion. Its first product offers continuous lactate monitoring, giving athletes real-time data on fatigue and endurance that previously required invasive blood tests. This investment taps into a rapidly growing sector, with the global wearable patch market valued at over $9.9 billion in 2024 and projected to exceed $22 billion by 2034. The market's growth is largely driven by the demand for remote monitoring of chronic conditions and the shift toward connected devices that stream real-time data to users and clinicians. Other startups are also attracting significant capital for similar patch-based biosensors. Biolinq recently raised $100 million for a wearable that measures glucose levels just beneath the skin's surface, while VitalConnect secured $100 million for its remote cardiac monitoring patches. The next wave of innovation in this space involves integrating AI and machine learning to interpret the vast datasets generated by these sensors, providing predictive and personalized health insights. This aligns with a broader venture capital trend, where AI-enabled startups received 62% of all digital health funding in 2025. Beyond athletics, PointFit plans to expand its modular platform to track a wider range of diagnostic biomarkers. This positions the technology for future applications in the larger and more lucrative markets of metabolic health management and longevity-focused personalized care.
